IC 700
Alternative Names: IC-700Latest Information Update: 28 May 2024
At a glance
- Originator ZyVersa Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Inflammasome inhibitors; PYCARD protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute lung injury
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Acute-lung-injury in USA
- 20 Apr 2020 IC 700 is available for licensing as of 20 Apr 2020. https://www.zyversa.com/pipeline/collaboration
- 20 Apr 2020 Preclinical trials in Acute lung injury in USA (unspecified route), prior to April 2020 (ZyVersa Therapeutics pipeline, April 2020)